Sotera Health (NASDAQ:SHC) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

by · The Cerbat Gem

Sotera Health (NASDAQ:SHC – Get Free Report) issued its earnings results on Tuesday. The company reported $0.17 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01), Briefing.com reports. The business had revenue of $285.47 million during the quarter, compared to analysts’ expectations of $278.64 million. Sotera Health had a return on equity of 47.26% and a net margin of 3.65%. Sotera Health’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same period last year, the firm posted $0.18 EPS. Sotera Health updated its FY 2024 guidance to 0.670-0.750 EPS and its FY24 guidance to $0.67-0.75 EPS.

Sotera Health Stock Performance

SHC traded down $0.28 on Thursday, hitting $15.83. 1,349,204 shares of the company traded hands, compared to its average volume of 1,307,183. The company has a 50 day moving average of $15.96 and a 200-day moving average of $13.69. The company has a quick ratio of 2.59, a current ratio of 2.93 and a debt-to-equity ratio of 5.46. The stock has a market capitalization of $4.48 billion, a PE ratio of 63.40 and a beta of 2.08. Sotera Health has a 12-month low of $10.71 and a 12-month high of $17.44.

Insider Transactions at Sotera Health

In related news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $15.03, for a total value of $150,300,000.00. Following the transaction, the director now directly owns 49,215,301 shares of the company’s stock, valued at approximately $739,705,974.03. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 55.12% of the company’s stock.

Analyst Ratings Changes

SHC has been the topic of a number of research analyst reports. Royal Bank of Canada reissued an “outperform” rating and issued a $17.00 price target on shares of Sotera Health in a report on Tuesday, August 6th. Citigroup increased their price target on Sotera Health from $18.00 to $20.00 and gave the stock a “buy” rating in a research report on Wednesday. Finally, Barclays raised their price objective on Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.50.

Get Our Latest Report on SHC

Sotera Health Company Profile

(Get Free Report)

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.

Read More